Faron Pharmaceuticals Oy

FARN.L

Biotechnology · Healthcare

Price

41.00 GBp

+0.50 (+1.23%)

Market Cap

£81.2M

Exchange

London Stock Exchange

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Share count rising — dilution

+75.4% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 61.3M (2021) → 107.6M (2025)

Winston Score History

The full picture

Faron Pharmaceuticals is a small Finnish biotech company that develops experimental medicines for serious diseases, mainly cancer and inflammatory conditions. Its most advanced drug candidate is bexmarilimab, which is designed to help the immune system fight certain blood cancers and solid tumors. The company does not yet sell any approved products and is focused entirely on clinical-stage research.

Faron earns no product revenue today. It funds its operations through equity raises, grants, and potential partnership deals with larger pharmaceutical companies. Based in Turku, Finland, it operates primarily in Europe but runs clinical trials internationally. With a market cap of around $100 million and deeply negative returns on capital, the company carries significant financial risk typical of early-stage biotechs. The key question for Faron is whether bexmarilimab can produce strong enough clinical trial results to attract a major pharma partner or gain regulatory approval, without running out of cash first.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

-32.7% YoY

YoY Growth Rate

Earnings declining

R&D Spend

€12M/ year

↑ Rising (+106030% vs prior year)

R&D investment increasing — building for the future

Insider Activity

54.3%ownership

↑ Rising

Insiders increasing their stake — aligned with shareholders

Cash Runway

~3 months

€12M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Short runway — potential dilution ahead through share issuance

Cash watch

Faron Pharmaceuticals Oy has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

—

Data not available

Profit after running costs

Operating Margin

N/A

—

Data not available

Return on the money invested

ROCE

-140.0%

Weak — -140.0% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

—

Data not available

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

5/8 quarters

Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial